kabutan

JCR Pharmaceuticals Co.,Ltd.(4552) Summary

4552
TSE Prime
JCR Pharmaceuticals Co.,Ltd.
615
JPY
-7
(-1.13%)
Mar 13, 3:30 pm JST
3.85
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
615.6
Mar 13, 7:51 pm JST
Summary Chart Historical News Financial Result
PER
46.8
PBR
1.62
Yield
3.25%
Margin Trading Ratio
17.02
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
616 JPY 3.86 USD
Previous Close Mar 12
622 JPY 3.91 USD
High Mar 13, 10:15 am
624 JPY 3.92 USD
Low Mar 13, 9:08 am
609 JPY 3.82 USD
Volume
363,000
Trading Value
0.22B JPY 1.40M USD
VWAP
616.71 JPY 3.87 USD
Minimum Trading Value
61,500 JPY 385 USD
Market Cap
0.08T JPY 0.50B USD
Number of Trades
548
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,272
1-Year High Jun 2, 2025
15,312
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 282,900 2,527,700 8.93
Feb 27, 2026 259,000 2,380,500 9.19
Feb 20, 2026 255,800 2,475,200 9.68
Feb 13, 2026 227,000 2,468,900 10.88
Feb 6, 2026 224,200 2,542,100 11.34
Company Profile
JCR Pharmaceuticals Co., Ltd. specializes in growth hormone products and focuses on biosimilars. The company collaborates with PeptiDream in creating carrier peptides.
Sector
Pharmaceuticals
JCR Pharmaceuticals Co., Ltd. develops, manufactures, and sells medical pharmaceuticals, regenerative medicine-related products, and pharmaceutical raw materials, primarily targeting rare disease areas. Through its group companies, the company engages in a wide range of activities including purchasing, facility management, market research, clinical trial supervision, pharmaceutical development, and intellectual property management. Internationally, JCR has subsidiaries in Brazil, Europe, and the United States, which handle clinical operations, regulatory affairs, and development tasks. The company also manages the distribution of pharmaceuticals and their raw materials, as well as contract manufacturing. JCR has affiliated companies involved in research and development, manufacturing, and sales in the regenerative medicine field, and has a proven track record in biosimilars.